Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-EGFRvIII in EGFRvIII+ Glioblastoma
NCT02209376Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Nov 2014
- Primary completion
- Apr 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EGFRvIII CAR-T in glioblastoma (GBM), sponsored by University of Pennsylvania. Primary endpoint: Number of adverse events at 2 years. Started Nov 2014; status: terminated.
02
Drugs
EGFRvIII CAR-T
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02209376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02209376.